Literature DB >> 31620220

Inhibitors of KRAS May Potentially Provide Effective Cancer Treatment.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2019        PMID： 31620220      PMCID： PMC6792154          DOI： 10.1021/acsmedchemlett.9b00428

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  3 in total

Review 1.  Drugging K-RasG12C through covalent inhibitors: Mission possible?

Authors:  Duan Ni; Xinyi Li; Xinheng He; Hao Zhang; Jian Zhang; Shaoyong Lu
Journal:  Pharmacol Ther       Date:  2019-06-22       Impact factor: 12.310

Review 2.  Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma.

Authors:  Jens Kohler; Marco Catalano; Chiara Ambrogio
Journal:  Curr Med Chem       Date:  2018-02-13       Impact factor: 4.530

Review 3.  Pharmacological targeting of RAS: Recent success with direct inhibitors.

Authors:  John P O'Bryan
Journal:  Pharmacol Res       Date:  2018-10-23       Impact factor: 7.658
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.